O	0	8	Clinical
O	9	12	and
O	13	20	Genomic
O	21	25	Risk
O	26	28	to
O	29	34	Guide
O	35	38	the
O	39	42	Use
O	43	45	of
B-intervention	46	54	Adjuvant
I-intervention	55	62	Therapy
O	63	66	for
O	67	73	Breast
O	74	80	Cancer
O	80	81	.

O	82	85	The
O	86	89	use
O	90	92	of
O	93	101	adjuvant
O	102	114	chemotherapy
O	115	117	in
O	118	126	patients
O	127	131	with
O	132	138	breast
O	139	145	cancer
O	146	149	may
O	150	152	be
O	153	159	guided
O	160	162	by
O	163	182	clinicopathological
O	183	190	factors
O	191	194	and
O	195	196	a
O	197	202	score
O	203	208	based
O	209	211	on
O	212	213	a
O	214	216	21
O	216	217	-
O	217	221	gene
O	222	227	assay
O	228	230	to
O	231	240	determine
O	241	244	the
O	245	249	risk
O	250	252	of
O	253	263	recurrence
O	263	264	.

O	265	272	Whether
O	273	276	the
O	277	282	level
O	283	285	of
O	286	294	clinical
O	295	299	risk
O	300	302	of
O	303	309	breast
O	310	316	cancer
O	317	327	recurrence
O	328	332	adds
O	333	343	prognostic
O	344	355	information
O	356	358	to
O	359	362	the
O	363	373	recurrence
O	374	379	score
O	380	382	is
O	383	386	not
O	387	392	known
O	392	393	.

O	394	396	We
O	397	406	performed
O	407	408	a
O	409	420	prospective
O	421	426	trial
O	427	436	involving
B-total-participants	437	441	9427
B-eligibility	442	447	women
I-eligibility	448	452	with
I-eligibility	453	460	hormone
I-eligibility	460	461	-
I-eligibility	461	469	receptor
I-eligibility	469	470	-
I-eligibility	470	478	positive
I-eligibility	478	479	,
I-eligibility	480	485	human
I-eligibility	486	495	epidermal
I-eligibility	496	502	growth
I-eligibility	503	509	factor
I-eligibility	510	518	receptor
I-eligibility	519	520	2
I-eligibility	520	521	-
I-eligibility	521	529	negative
I-eligibility	529	530	,
I-eligibility	531	539	axillary
I-eligibility	540	544	node
I-eligibility	544	545	-
I-eligibility	545	553	negative
I-eligibility	554	560	breast
I-eligibility	561	567	cancer
I-eligibility	567	568	,
I-eligibility	569	571	in
I-eligibility	572	576	whom
I-eligibility	577	579	an
I-eligibility	580	585	assay
I-eligibility	586	588	of
I-eligibility	589	591	21
I-eligibility	592	597	genes
I-eligibility	598	601	had
I-eligibility	602	606	been
I-eligibility	607	616	performed
O	616	617	,
O	618	621	and
O	622	624	we
O	625	635	classified
O	636	639	the
O	640	648	clinical
O	649	653	risk
O	654	656	of
O	657	667	recurrence
O	668	670	of
O	671	677	breast
O	678	684	cancer
O	685	687	as
O	688	691	low
O	692	694	or
O	695	699	high
O	700	702	on
O	703	706	the
O	707	712	basis
O	713	715	of
O	716	719	the
O	720	725	tumor
O	726	730	size
O	731	734	and
O	735	745	histologic
O	746	751	grade
O	751	752	.

O	753	756	The
O	757	763	effect
O	764	766	of
O	767	775	clinical
O	776	780	risk
O	781	784	was
O	785	794	evaluated
O	795	797	by
O	798	809	calculating
O	810	816	hazard
O	817	823	ratios
O	824	827	for
O	828	835	distant
O	836	846	recurrence
O	847	851	with
O	852	855	the
O	856	859	use
O	860	862	of
O	863	866	Cox
O	867	879	proportional
O	879	880	-
O	880	887	hazards
O	888	894	models
O	894	895	.

O	896	899	The
O	900	907	initial
O	908	917	endocrine
O	918	925	therapy
O	926	929	was
O	930	939	tamoxifen
O	940	945	alone
O	946	948	in
O	949	952	the
O	953	961	majority
O	962	964	of
O	965	968	the
O	969	982	premenopausal
O	983	988	women
O	989	992	who
O	993	997	were
O	998	1000	50
O	1001	1006	years
O	1007	1009	of
O	1010	1013	age
O	1014	1016	or
O	1017	1024	younger
O	1024	1025	.

O	1026	1029	The
B-outcome	1030	1035	level
I-outcome	1036	1038	of
I-outcome	1039	1047	clinical
I-outcome	1048	1052	risk
O	1053	1056	was
O	1057	1067	prognostic
O	1068	1070	of
O	1071	1078	distant
O	1079	1089	recurrence
O	1090	1092	in
O	1093	1098	women
O	1099	1103	with
O	1104	1106	an
O	1107	1119	intermediate
O	1120	1122	21
O	1122	1123	-
O	1123	1127	gene
O	1128	1138	recurrence
O	1139	1144	score
O	1145	1147	of
O	1148	1150	11
O	1151	1153	to
O	1154	1156	25
O	1157	1158	(
O	1158	1160	on
O	1161	1162	a
O	1163	1168	scale
O	1169	1171	of
O	1172	1173	0
O	1174	1176	to
O	1177	1180	100
O	1180	1181	,
O	1182	1186	with
O	1187	1193	higher
O	1194	1200	scores
O	1201	1211	indicating
O	1212	1213	a
O	1214	1219	worse
O	1220	1229	prognosis
O	1230	1232	or
O	1233	1234	a
O	1235	1242	greater
O	1243	1252	potential
O	1253	1260	benefit
O	1261	1265	from
O	1266	1278	chemotherapy
O	1278	1279	)
O	1280	1283	who
O	1284	1288	were
O	1289	1297	randomly
O	1298	1306	assigned
O	1307	1309	to
O	1310	1319	endocrine
O	1320	1327	therapy
O	1328	1329	(
O	1329	1335	hazard
O	1336	1341	ratio
O	1342	1345	for
O	1346	1349	the
O	1350	1360	comparison
O	1361	1363	of
O	1364	1368	high
O	1369	1371	vs
O	1371	1372	.
O	1373	1376	low
O	1377	1385	clinical
O	1386	1390	risk
O	1390	1391	,
O	1392	1393	2
O	1393	1394	.
O	1394	1396	73
O	1396	1397	;
O	1398	1400	95
O	1400	1401	%
O	1402	1412	confidence
O	1413	1421	interval
O	1422	1423	[
O	1423	1425	CI
O	1425	1426	]
O	1426	1427	,
O	1428	1429	1
O	1429	1430	.
O	1430	1432	93
O	1433	1435	to
O	1436	1437	3
O	1437	1438	.
O	1438	1440	87
O	1440	1441	)
O	1442	1444	or
O	1445	1447	to
O	1448	1460	chemotherapy
O	1461	1465	plus
O	1466	1475	endocrine
O	1476	1477	(
O	1477	1491	chemoendocrine
O	1491	1492	)
O	1493	1500	therapy
O	1501	1502	(
O	1502	1508	hazard
O	1509	1514	ratio
O	1514	1515	,
O	1516	1517	2
O	1517	1518	.
O	1518	1520	41
O	1520	1521	;
O	1522	1524	95
O	1524	1525	%
O	1526	1528	CI
O	1528	1529	,
O	1530	1531	1
O	1531	1532	.
O	1532	1534	66
O	1535	1537	to
O	1538	1539	3
O	1539	1540	.
O	1540	1542	48
O	1542	1543	)
O	1544	1547	and
O	1548	1550	in
O	1551	1556	women
O	1557	1561	with
O	1562	1563	a
O	1564	1568	high
O	1569	1579	recurrence
O	1580	1585	score
O	1586	1587	(
O	1587	1588	a
O	1589	1594	score
O	1595	1597	of
O	1598	1600	26
O	1601	1603	to
O	1604	1607	100
O	1607	1608	)
O	1608	1609	,
O	1610	1613	all
O	1614	1616	of
O	1617	1621	whom
O	1622	1626	were
O	1627	1635	assigned
O	1636	1638	to
O	1639	1653	chemoendocrine
O	1654	1661	therapy
O	1662	1663	(
O	1663	1669	hazard
O	1670	1675	ratio
O	1675	1676	,
O	1677	1678	3
O	1678	1679	.
O	1679	1681	17
O	1681	1682	;
O	1683	1685	95
O	1685	1686	%
O	1687	1689	CI
O	1689	1690	,
O	1691	1692	1
O	1692	1693	.
O	1693	1695	94
O	1696	1698	to
O	1699	1700	5
O	1700	1701	.
O	1701	1703	19
O	1703	1704	)
O	1704	1705	.

O	1706	1711	Among
O	1712	1717	women
O	1718	1721	who
O	1722	1726	were
O	1727	1729	50
O	1730	1735	years
O	1736	1738	of
O	1739	1742	age
O	1743	1745	or
O	1746	1753	younger
O	1754	1757	who
O	1758	1761	had
O	1762	1770	received
O	1771	1780	endocrine
O	1781	1788	therapy
O	1789	1794	alone
O	1794	1795	,
O	1796	1799	the
B-outcome	1800	1809	estimated
I-outcome	1810	1811	(
I-outcome	1811	1812	±
I-outcome	1812	1814	SE
I-outcome	1814	1815	)
I-outcome	1816	1820	rate
I-outcome	1821	1823	of
I-outcome	1824	1831	distant
I-outcome	1832	1842	recurrence
I-outcome	1843	1845	at
I-outcome	1846	1847	9
I-outcome	1848	1853	years
O	1854	1857	was
O	1858	1862	less
O	1863	1867	than
O	1868	1869	5
O	1869	1870	%
O	1871	1872	(
O	1872	1873	≤
O	1873	1874	1
O	1874	1875	.
O	1875	1876	8
O	1876	1877	±
O	1877	1878	0
O	1878	1879	.
O	1879	1880	9
O	1880	1881	%
O	1881	1882	)
O	1883	1887	with
O	1888	1889	a
O	1890	1893	low
B-outcome	1894	1904	recurrence
I-outcome	1905	1910	score
O	1911	1912	(
O	1912	1913	a
O	1914	1919	score
O	1920	1922	of
O	1923	1924	0
O	1925	1927	to
O	1928	1930	10
O	1930	1931	)
O	1931	1932	,
O	1933	1945	irrespective
O	1946	1948	of
O	1949	1957	clinical
O	1958	1962	risk
O	1962	1963	,
O	1964	1967	and
O	1968	1969	4
O	1969	1970	.
O	1970	1971	7
O	1971	1972	±
O	1972	1973	1
O	1973	1974	.
O	1974	1975	0
O	1975	1976	%
O	1977	1981	with
O	1982	1984	an
O	1985	1997	intermediate
O	1998	2008	recurrence
O	2009	2014	score
O	2015	2018	and
O	2019	2022	low
O	2023	2031	clinical
O	2032	2036	risk
O	2036	2037	.

O	2038	2040	In
O	2041	2045	this
O	2046	2049	age
O	2050	2055	group
O	2055	2056	,
O	2057	2060	the
B-outcome	2061	2070	estimated
I-outcome	2071	2078	distant
I-outcome	2079	2089	recurrence
I-outcome	2090	2092	at
I-outcome	2093	2094	9
I-outcome	2095	2100	years
O	2101	2109	exceeded
O	2110	2112	10
O	2112	2113	%
O	2114	2119	among
O	2120	2125	women
O	2126	2130	with
O	2131	2132	a
O	2133	2137	high
O	2138	2146	clinical
O	2147	2151	risk
O	2152	2155	and
O	2156	2158	an
O	2159	2171	intermediate
O	2172	2182	recurrence
O	2183	2188	score
O	2189	2192	who
O	2193	2201	received
O	2202	2211	endocrine
O	2212	2219	therapy
O	2220	2225	alone
O	2226	2227	(
O	2227	2229	12
O	2229	2230	.
O	2230	2231	3
O	2231	2232	±
O	2232	2233	2
O	2233	2234	.
O	2234	2235	4
O	2235	2236	%
O	2236	2237	)
O	2238	2241	and
O	2242	2247	among
O	2248	2253	those
O	2254	2258	with
O	2259	2260	a
O	2261	2265	high
O	2266	2276	recurrence
O	2277	2282	score
O	2283	2286	who
O	2287	2295	received
O	2296	2310	chemoendocrine
O	2311	2318	therapy
O	2319	2320	(
O	2320	2322	15
O	2322	2323	.
O	2323	2324	2
O	2324	2325	±
O	2325	2326	3
O	2326	2327	.
O	2327	2328	3
O	2328	2329	%
O	2329	2330	)
O	2330	2331	.

O	2332	2340	Clinical
O	2340	2341	-
O	2341	2345	risk
O	2346	2360	stratification
O	2361	2369	provided
O	2370	2380	prognostic
O	2381	2392	information
O	2393	2397	that
O	2397	2398	,
O	2399	2403	when
O	2404	2409	added
O	2410	2412	to
O	2413	2416	the
O	2417	2419	21
O	2419	2420	-
O	2420	2424	gene
O	2425	2435	recurrence
O	2436	2441	score
O	2441	2442	,
O	2443	2448	could
O	2449	2451	be
O	2452	2456	used
O	2457	2459	to
O	2460	2468	identify
O	2469	2482	premenopausal
O	2483	2488	women
O	2489	2492	who
O	2493	2498	could
O	2499	2506	benefit
O	2507	2511	from
O	2512	2516	more
O	2517	2526	effective
O	2527	2534	therapy
O	2534	2535	.

O	2536	2537	(
O	2537	2543	Funded
O	2544	2546	by
O	2547	2550	the
O	2551	2559	National
O	2560	2566	Cancer
O	2567	2576	Institute
O	2577	2580	and
O	2581	2587	others
O	2587	2588	;
O	2589	2603	ClinicalTrials
O	2603	2604	.
O	2604	2607	gov
O	2608	2614	number
O	2614	2615	,
O	2616	2627	NCT00310180
O	2627	2628	.
O	2628	2629	)
O	2629	2630	.
